EDGEWELL PERSONAL CARE Co — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EDGEWELL PERSONAL CARE Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.22B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $2.25B | Nov 18, 2025 |
| FY2023 | Sep 30, 2023 | $534.10M | Nov 28, 2023 |
| FY2023 | Jun 30, 2023 | $650.00M | Nov 28, 2023 |
| FY2023 | Mar 31, 2023 | $598.40M | Nov 28, 2023 |
| FY2023 | Dec 31, 2022 | $469.10M | Nov 28, 2023 |
| FY2023 | Sep 30, 2022 | $536.90M | Nov 28, 2023 |
| FY2023 | Jun 30, 2022 | $623.80M | Nov 28, 2023 |
| FY2023 | Mar 31, 2022 | $547.70M | Nov 28, 2023 |
| FY2023 | Dec 31, 2021 | $463.30M | Nov 28, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $924.90M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $955.70M | Nov 18, 2025 |
| FY2023 | Sep 30, 2023 | $228.60M | Nov 28, 2023 |
| FY2023 | Jun 30, 2023 | $280.30M | Nov 28, 2023 |
| FY2023 | Mar 31, 2023 | $242.30M | Nov 28, 2023 |
| FY2023 | Dec 31, 2022 | $189.60M | Nov 28, 2023 |
| FY2023 | Sep 30, 2022 | $219.00M | Nov 28, 2023 |
| FY2023 | Jun 30, 2022 | $240.90M | Nov 28, 2023 |
| FY2023 | Mar 31, 2022 | $230.40M | Nov 28, 2023 |
| FY2023 | Dec 31, 2021 | $190.20M | Nov 28, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $25.40M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $98.60M | Nov 18, 2025 |
| FY2023 | Sep 30, 2023 | $29.90M | Nov 28, 2023 |
| FY2023 | Jun 30, 2023 | $53.00M | Nov 28, 2023 |
| FY2023 | Mar 31, 2023 | $19.40M | Nov 28, 2023 |
| FY2023 | Dec 31, 2022 | $12.40M | Nov 28, 2023 |
| FY2023 | Sep 30, 2022 | $33.70M | Nov 28, 2023 |
| FY2023 | Jun 30, 2022 | $30.80M | Nov 28, 2023 |
| FY2023 | Mar 31, 2022 | $23.50M | Nov 28, 2023 |
| FY2023 | Dec 31, 2021 | $11.50M | Nov 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $96.60M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $199.30M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $227.00M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $182.30M | Nov 14, 2024 |
| FY2023 | Sep 30, 2021 | $239.90M | Nov 28, 2023 |
| FY2022 | Sep 30, 2020 | $176.00M | Nov 16, 2022 |
| FY2021 | Sep 30, 2019 | $243.80M | Nov 19, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $57.60M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $58.40M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $58.50M | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $55.50M | Nov 14, 2024 |
| FY2023 | Sep 30, 2021 | $57.80M | Nov 28, 2023 |
| FY2022 | Sep 30, 2020 | $55.30M | Nov 16, 2022 |
| FY2021 | Sep 30, 2019 | $53.50M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $61.10M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $67.60M | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $71.90M | Nov 19, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $425.00M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $430.10M | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $409.60M | Nov 18, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $118.40M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | ($231.00M) | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | ($216.10M) | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $102.00M | Nov 14, 2024 |
| FY2023 | Sep 30, 2021 | $229.00M | Nov 28, 2023 |
| FY2022 | Sep 30, 2020 | $232.60M | Nov 16, 2022 |
| FY2021 | Sep 30, 2019 | $190.60M | Nov 19, 2021 |
| FY2020 | Sep 30, 2018 | $259.40M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $313.60M | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $186.80M | Nov 19, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Sep 30, 2014 | $85.30M | Nov 18, 2014 |
| FY2014 | Sep 30, 2013 | $90.60M | Nov 18, 2014 |
| FY2014 | Sep 30, 2012 | $111.00M | Nov 18, 2014 |
| FY2013 | Sep 30, 2011 | $98.00M | Nov 21, 2013 |
| FY2012 | Sep 30, 2010 | $108.70M | Nov 20, 2012 |
| FY2011 | Sep 30, 2009 | $139.70M | Nov 22, 2011 |
| FY2010 | Sep 30, 2008 | $160.00M | Nov 23, 2010 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.76B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $3.73B | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | $3.74B | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | $3.71B | Nov 28, 2023 |
| FY2022 | Sep 30, 2021 | $3.67B | Nov 16, 2022 |
| FY2021 | Sep 30, 2020 | $3.54B | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | $3.42B | Nov 20, 2020 |
| FY2019 | Jun 30, 2019 | $3.43B | Nov 26, 2019 |
| FY2019 | Sep 30, 2018 | $3.95B | Nov 26, 2019 |
| FY2018 | Sep 30, 2017 | $4.19B | Nov 19, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.20B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $2.15B | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | $2.20B | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | $2.25B | Nov 28, 2023 |
| FY2022 | Sep 30, 2021 | $2.09B | Nov 16, 2022 |
| FY2021 | Sep 30, 2020 | $2.11B | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | $2.12B | Nov 20, 2020 |
| FY2019 | Jun 30, 2019 | $2.10B | Nov 26, 2019 |
| FY2019 | Sep 30, 2018 | $2.21B | Nov 26, 2019 |
| FY2018 | Sep 30, 2017 | $2.45B | Nov 19, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.55B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $1.58B | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $1.54B | Nov 18, 2025 |
| FY2025 | Sep 30, 2022 | $1.47B | Nov 18, 2025 |
| FY2024 | Sep 30, 2021 | $1.59B | Nov 14, 2024 |
| FY2023 | Sep 30, 2020 | $1.44B | Nov 28, 2023 |
| FY2022 | Sep 30, 2019 | $1.30B | Nov 16, 2022 |
| FY2019 | Jun 30, 2019 | $1.34B | Nov 26, 2019 |
| FY2021 | Sep 30, 2018 | $1.74B | Nov 19, 2021 |
| FY2020 | Sep 30, 2017 | $1.74B | Nov 20, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.29B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $1.34B | Nov 18, 2025 |
| FY2025 | Sep 30, 2023 | $1.33B | Nov 18, 2025 |
| FY2024 | Sep 30, 2022 | $1.32B | Nov 14, 2024 |
| FY2023 | Sep 30, 2021 | $1.16B | Nov 28, 2023 |
| FY2022 | Sep 30, 2020 | $1.16B | Nov 16, 2022 |
| FY2021 | Sep 30, 2019 | $1.03B | Nov 19, 2021 |
| FY2019 | Jun 30, 2019 | $1.04B | Nov 26, 2019 |
| FY2020 | Sep 30, 2018 | $1.45B | Nov 20, 2020 |
| FY2018 | Sep 30, 2017 | $1.45B | Nov 19, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.09B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $1.09B | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | $1.02B | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | $939.10M | Nov 28, 2023 |
| FY2022 | Sep 30, 2021 | $865.70M | Nov 16, 2022 |
| FY2021 | Sep 30, 2020 | $782.40M | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | $714.80M | Nov 20, 2020 |
| FY2019 | Jun 30, 2019 | $674.10M | Nov 26, 2019 |
| FY2019 | Sep 30, 2018 | $1.08B | Nov 26, 2019 |
| FY2018 | Sep 30, 2017 | $952.90M | Nov 19, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $209.10M | Nov 14, 2024 |
| FY2024 | Sep 30, 2023 | $216.40M | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | $188.70M | Nov 28, 2023 |
| FY2022 | Sep 30, 2021 | $479.20M | Nov 16, 2022 |
| FY2021 | Sep 30, 2020 | $364.70M | Nov 19, 2021 |
| FY2021 | Sep 30, 2019 | $341.60M | Nov 19, 2021 |
| FY2021 | Sep 30, 2018 | $266.40M | Nov 19, 2021 |
| FY2020 | Sep 30, 2017 | $502.90M | Nov 20, 2020 |
| FY2019 | Sep 30, 2016 | $738.90M | Nov 26, 2019 |
| FY2018 | Sep 30, 2015 | $712.10M | Nov 19, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.39B | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | $1.28B | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | $1.37B | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | $1.41B | Nov 28, 2023 |
| FY2022 | Sep 30, 2021 | $1.25B | Nov 16, 2022 |
| FY2021 | Sep 30, 2020 | $1.25B | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | $1.22B | Nov 20, 2020 |
| FY2019 | Sep 30, 2018 | $1.29B | Nov 26, 2019 |
| FY2018 | Sep 30, 2017 | $1.53B | Nov 19, 2018 |
| FY2017 | Sep 30, 2016 | $1.83B | Nov 20, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | 1 | Nov 18, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Nov 28, 2023 |
| FY2023 | Jun 30, 2023 | 1 | Nov 28, 2023 |
| FY2023 | Mar 31, 2023 | 0 | Nov 28, 2023 |
| FY2023 | Dec 31, 2022 | 0 | Nov 28, 2023 |
| FY2023 | Sep 30, 2022 | 0 | Nov 28, 2023 |
| FY2023 | Jun 30, 2022 | 0 | Nov 28, 2023 |
| FY2023 | Mar 31, 2022 | 0 | Nov 28, 2023 |
| FY2023 | Dec 31, 2021 | 0 | Nov 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | 1 | Nov 18, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Nov 28, 2023 |
| FY2023 | Jun 30, 2023 | 1 | Nov 28, 2023 |
| FY2023 | Mar 31, 2023 | 0 | Nov 28, 2023 |
| FY2023 | Dec 31, 2022 | 0 | Nov 28, 2023 |
| FY2023 | Sep 30, 2022 | 0 | Nov 28, 2023 |
| FY2023 | Jun 30, 2022 | 0 | Nov 28, 2023 |
| FY2023 | Mar 31, 2022 | 0 | Nov 28, 2023 |
| FY2023 | Dec 31, 2021 | 0 | Nov 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 46.46M | Nov 18, 2025 |
| FY2025 | Sep 30, 2024 | 48.92M | Nov 18, 2025 |
| FY2024 | Sep 30, 2023 | 50.12M | Nov 14, 2024 |
| FY2023 | Sep 30, 2022 | 51.57M | Nov 28, 2023 |
| FY2022 | Sep 30, 2021 | 54.37M | Nov 16, 2022 |
| FY2021 | Sep 30, 2020 | 54.36M | Nov 19, 2021 |
| FY2020 | Sep 30, 2019 | 54.21M | Nov 20, 2020 |
| FY2019 | Sep 30, 2018 | 54.04M | Nov 26, 2019 |
| FY2018 | Sep 30, 2017 | 56.02M | Nov 19, 2018 |
| FY2017 | Sep 30, 2016 | 57.91M | Nov 20, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $0 | Nov 20, 2017 |
| FY2017 | Sep 30, 2016 | $0 | Nov 20, 2017 |
| FY2017 | Sep 30, 2015 | $93.20M | Nov 20, 2017 |
| FY2016 | Sep 30, 2014 | $123.90M | Nov 18, 2016 |